19338-43-3

Basic information

• Product Name: 5-(4-fluorophenyl)-1,3-oxazolidin-2-one
• Synonyms: 5-(4-fluorophenyl)-1,3-oxazolidin-2-one
• CAS NO: 19338-43-3
• Molecular Weight: 181.166
• Mol File: 19338-43-3.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 5-(4-fluorophenyl)-1,3-oxazolidin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(4-fluorophenyl)-1,3-oxazolidin-2-one(19338-43-3)
• EPA Substance Registry System: 5-(4-fluorophenyl)-1,3-oxazolidin-2-one(19338-43-3)

Safety Data

• Hazardous Substances Data: 19338-43-3(Hazardous Substances Data)

Upstream product

• 75-44-5 phosgene 
• 456-05-3 2-amino-1-(4-fluorophenyl)ethanol 
• 18511-66-5 2-(4-fluorophenyl)aziridine 
• 124-38-9 carbon dioxide 
• 18511-62-1 4-fluorostyrene oxide 
• 917-61-3 sodium isocyanate 
• 864539-93-5 tert-butyl [2-(4-fluorophenyl)-2-hydroxyethyl]carbamate 
• 877319-43-2 tert-butyl (2-(4-fluorophenyl)-2-oxoethyl)carbamate 

Downstream Products

• 451-45-6 1-(4-fluoro-phenyl)-2-methylamino-ethanol 
• 20805-28-1 5-(4-fluorophenyl)-3-methyloxazolidin-2-one 

Relevant articles and documents

Identification of (6S)-cyclopropyl-6,7-dihydropyrazolo[1,5-a]pyrazine-5(4H)-carboxamines as new HBV capsid assembly modulators

GYH2-18 is a type II HBV CAM with 6,7-dihydropyrazolo[1,5-a]pyrazine-5(4H)-carboxamine (DPPC) skeleton discovered by Roche INC. A series of GYH2-18 derivatives were designed, synthesized and evaluated for their anti-HBV activity. Two compounds 2f and 3k exhibited excellent anti-HBV activity, low cytotoxicity and accepted oral PK profiles. Chiral separation of 2f and 3k was conducted successfully, and (6S)-cyclopropyl DPPC isomers 2f-1, 2f-3, 3k-1 and 3k-3 were identified to be much more active than the corresponding (6R)-ones. The preliminary structure-activity relationship, particle gel assay and molecular modeling studies were also discussed, which provide useful indications for guiding the further rational design of new (6S)-cyclopropyl DPPC analogues.

Regioselective Ring-Opening of Styrene Oxide Derivatives Using Halohydrin Dehalogenase for Synthesis of 4-Aryloxazolidinones

A biocatalytic approach towards a range of 4-aryloxazolidinones is developed using a halohydrin dehalogenase from Ilumatobacter coccineus (HheG) as biocatalyst. The method is based on the HheG-catalyzed α-position regioselective ring-opening of styrene oxide derivatives with cyanate as a nucleophile, producing the corresponding 4-aryloxazolidinones in moderate to good yields. Synthesis of enantiopure 4-aryloxazolidinones is also achievable using chiral epoxide materials. (Figure presented.).

OXAZOLIDINONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS

The present invention is directed to compounds of Formula (I): Wherein R1, R2, Y, m and n are further defined in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.